Tags Archives: COVID-19

Perfusfind S.L.

Abstract PRINCETON, N.J., Nov. 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: ), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using its CytoSorb® blood purification technology,..

Perfusfind S.L.

Abstract According to a recent study designed to evaluate the efficacy and feasibility of lung transplantation for respiratory failure from COVID-19, transplantation can produce acceptable results if it is performed..

Perfusfind S.L.

Abstract Background Venovenous extracorporeal membrane oxygenation (ECMO) can be considered for patients with COVID-19-associated acute respiratory distress syndrome (ARDS) who continue to deteriorate despite evidence-based therapies and lung-protective ventilation. The..

Perfusfind S.L.

This case reports on a 12-year-old male patient (weight 55 kg) without relevant medical history, who was admitted to the hospital with a three days history of fever associated with..

Perfusfind S.L.

Abstract Objectives Refractory hypoxemia can occur in patients with acute respiratory distress syndrome from COVID-19 despite support with venovenous (VV) extracorporeal membrane oxygenation (ECMO). Parallel ECMO circuits can be used..

Perfusfind S.L.

Abstract Background The aim was to analyze routine preoperative testing for coronavirus disease 2019 (COVID-19) performed to avoid infected cardiac surgical patients transmitting virus during the pandemic. Methods Every patient..

Perfusfind S.L.

Abstract The provision of cardiac surgery services nationwide has been affected by the COVID-19 pandemic. We noticed a high COVID-19 mortality rate in unvaccinated patients who were diagnosed with COVID-19..

Perfusfind S.L.

Abstract During a 6 week period beginning early March 2020, 30 patients with severe coronavirus disease 2019 (COVID-19) were supported with venovenous extracorporeal membrane oxygenation (ECMO). This volume increase mandated..

Perfusfind S.L.

Abstract Clinical presentation and mortality of patients treated with extracorporeal membrane oxygenation (ECMO) for COVID-19 acute respiratory distress syndrome (CARDS) were different during the French epidemic waves. The management of..

Perfusfind S.L.

Abstract Introduction Veno-venous extracorporeal membrane oxygenation (VV ECMO) has become a support modality for patients with acute respiratory failure refractory to standard therapies. VV ECMO has been increasingly used during..

Perfusfind S.L.

Abstract Background: Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO) is one effective treatment for COVID-19 pneumonia, but controversy regarding VV-ECMO management in obese patients still exists. In this report, we described a case..

Perfusfind S.L.

Abstract Rational. Long-term outcomes of patients with COVID-19-related acute respiratory distress syndrome (ARDS) treated with extracorporeal membrane oxygenation (ECMO) are unknown. Methods. Multicenter, prospective study in patients who received ECMO..

Perfusfind S.L.

Abstract Introduction: Immunomodulatory therapies have shown beneficial effects in patients with severe COVID-19. Patients with hypercytokinemia might benefit from the removal of inflammatory mediators via hemadsorption. Methods: Single-center prospective randomized trial at..

Perfusfind S.L.

Abstract We aimed to assess the efficacy and safety of extracorporeal membrane oxygenation (ECMO) in patients under mechanical ventilation with COVID-19 and severe acute respiratory distress syndrome (ARDS). A systematic..

Perfusfind S.L.

Abstract During the coronavirus disease (COVID-19) pandemic, the number of patients eligible to receive extracorporeal membrane oxygenation (ECMO) has exceeded the availability of this resource-intensive therapy (). To maximize benefit,..

Perfusfind S.L.

Abstract Introduction: Immunomodulatory therapies have shown beneficial effects in patients with severe COVID-19. Patients with hypercytokinemia might benefit from the removal of inflammatory mediators via hemadsorption. Methods: Single-center prospective randomized trial at..

Perfusfind S.L.

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been associated with the significant use of venovenous extracorporeal membrane oxygenation (VVECMO) globally. Identifying strategies to optimize care is essential to improving..

Perfusfind S.L.

Abstract An extracorporeal membrane oxygenation (ECMO) program is an important component in the management of patients with COVID-19, but it is imperative to implement a system that is well-supported by..

Perfusfind S.L.

Abstract Venovenous extracorporeal membrane oxygenation (VV ECMO) has been used to treat severe coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome; however, patient selection criteria have evolved throughout the pandemic...

Perfusfind S.L.

Abstract The aim of this retrospective multicenter observational study is to test the feasibility and safety of a combined extracorporeal CO2 removal (ECCO2R) plus renal replacement therapy (RRT) system to use..

Perfusfind S.L.

90 years old male with COVID 19 and mitral valve endocarditis and abcess formation undergone MVR with cardiamed valve LA infection removal and irrigation and LA closure.   [playlist ids="30922"]..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is increasingly being used for patients with severe respiratory failure and has received particular attention during the coronavirus disease 2019 (COVID-19) pandemic. Evidence from two..

Perfusfind S.L.

Abstract In appropriately selected patients with COVID-19 acute respiratory distress syndrome, venovenous extracorporeal membrane oxygenation (VV ECMO) may offer a promising bridge to lung recovery or lung transplantation if lung recovery..

Perfusfind S.L.

Abstract Background Severe COVID-19 induced acute respiratory distress syndrome (ARDS) often requires extracorporeal membrane oxygenation (ECMO). Recent German health insurance data revealed low ICU survival rates. Patient characteristics and experience..

Perfusfind S.L.

Abstract First described early in the pandemic, coronavirus disease 2019 (COVID-19)-associated fulminant myocarditis can present with arrhythmias and cardiogenic shock, but may be treatable with mechanical circulatory support, such as..

Perfusfind S.L.

Abstract Sustained hypercoagulability and endotheliopathy are present in convalescent COVID-19 patients for up to 4 months from recovery. The hemostatic, endothelial, and inflammatory profiles of 39 recovered COVID-19 patients were evaluated..

Perfusfind S.L.

Abstract Purpose To describe bleeding and thrombotic events and their risk factors in patients receiving extracorporeal membrane oxygenation (ECMO) for severe coronavirus disease 2019 (COVID-19) and to evaluate their impact..

Perfusfind S.L.

Abstract A retrospective study was performed examining the trend of inflammatory markers, including D-dimers, in 29 COVID-19 patients requiring veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support. We observed that COVID-19..

Perfusfind S.L.

Abstract Background PEEP selection in severe COVID-19 patients under extracorporeal membrane oxygenation (ECMO) is challenging as no study has assessed the alveolar recruitability in this setting. The aim of the..

Perfusfind S.L.

Abstract Background Ever since COVID-19 was declared a pandemic, the world medical landscape has changed dramatically. As cardiac surgeons we not only have the duty to protect our patients and..